IL136584A - SUBSTITUTED beta-ALANINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF - Google Patents

SUBSTITUTED beta-ALANINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF

Info

Publication number
IL136584A
IL136584A IL13658498A IL13658498A IL136584A IL 136584 A IL136584 A IL 136584A IL 13658498 A IL13658498 A IL 13658498A IL 13658498 A IL13658498 A IL 13658498A IL 136584 A IL136584 A IL 136584A
Authority
IL
Israel
Prior art keywords
alanines
pharmaceutical compositions
compounds
substituted beta
prodrugs
Prior art date
Application number
IL13658498A
Other languages
English (en)
Other versions
IL136584A0 (en
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9727532.5A external-priority patent/GB9727532D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of IL136584A0 publication Critical patent/IL136584A0/xx
Publication of IL136584A publication Critical patent/IL136584A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Polyamides (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IL13658498A 1997-12-23 1998-12-23 SUBSTITUTED beta-ALANINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF IL136584A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9727532.5A GB9727532D0 (en) 1997-12-23 1997-12-23 Chemical compounds
US9260298P 1998-07-13 1998-07-13
PCT/GB1998/003859 WO1999033789A1 (en) 1997-12-23 1998-12-23 SUBSTITUTED β-ALANINES

Publications (2)

Publication Number Publication Date
IL136584A0 IL136584A0 (en) 2001-06-14
IL136584A true IL136584A (en) 2005-03-20

Family

ID=26312873

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13658498A IL136584A (en) 1997-12-23 1998-12-23 SUBSTITUTED beta-ALANINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF

Country Status (18)

Country Link
EP (1) EP1042279B1 (de)
JP (1) JP4555469B2 (de)
KR (1) KR20010033520A (de)
CN (1) CN1163477C (de)
AT (1) ATE289991T1 (de)
AU (1) AU747907B2 (de)
BR (1) BR9814376A (de)
CA (1) CA2316235A1 (de)
CZ (1) CZ20002342A3 (de)
DE (1) DE69829215T2 (de)
ES (1) ES2235383T3 (de)
HU (1) HUP0101701A3 (de)
IL (1) IL136584A (de)
NO (1) NO20003273L (de)
NZ (1) NZ505363A (de)
SK (1) SK9372000A3 (de)
TR (1) TR200001947T2 (de)
WO (1) WO1999033789A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1294576A (zh) * 1998-01-23 2001-05-09 诺瓦提斯公司 Vla-4拮抗剂
WO2000039103A1 (en) * 1998-12-23 2000-07-06 Aventis Pharma Limited Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines
CA2362831C (en) * 1999-02-18 2008-10-07 F. Hoffmann-La Roche Ag Thioamide derivatives
YU41202A (sh) * 1999-12-28 2005-03-15 Pfizer Products Inc. Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
DE10019755A1 (de) * 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
FR2812633A1 (fr) * 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
GB2367816A (en) 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
GB2369357A (en) * 2000-10-09 2002-05-29 Bayer Ag Aliphatic, cyclic amino carboxylic acids as integrin antagonists
CA2427750C (en) 2000-11-04 2011-01-04 Aventis Pharma Limited Substituted alkanoic acids
CA2430978C (en) 2000-12-28 2012-05-15 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
JP4676884B2 (ja) 2003-07-24 2011-04-27 第一三共株式会社 シクロヘキサンカルボン酸類
EP1874283A4 (de) * 2005-04-28 2011-11-02 Ferring Bv Verwendung neuer verbindungen zur behandlung von ibd
EP1961750B1 (de) 2005-12-13 2013-09-18 Daiichi Sankyo Company, Limited Vla-4-hemmendes arzneimittel
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
MX9801716A (es) * 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
DE69706407T2 (de) * 1996-03-29 2002-05-29 G.D. Searle & Co., Chicago META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
DK0891325T3 (da) * 1996-03-29 2002-05-21 Searle & Co Para-substituerede phenylpropansyrederivater som integrinantagonister
DK1027328T3 (da) * 1997-10-31 2006-11-13 Aventis Pharma Ltd Substituerede anilider

Also Published As

Publication number Publication date
CZ20002342A3 (cs) 2001-11-14
HUP0101701A2 (hu) 2001-11-28
CN1283181A (zh) 2001-02-07
IL136584A0 (en) 2001-06-14
JP2001527061A (ja) 2001-12-25
DE69829215T2 (de) 2005-07-21
NO20003273D0 (no) 2000-06-22
HK1034508A1 (en) 2001-10-26
NZ505363A (en) 2005-02-25
ES2235383T3 (es) 2005-07-01
TR200001947T2 (tr) 2001-01-22
EP1042279B1 (de) 2005-03-02
AU747907B2 (en) 2002-05-30
CA2316235A1 (en) 1999-07-08
BR9814376A (pt) 2000-10-10
DE69829215D1 (de) 2005-04-07
HUP0101701A3 (en) 2003-02-28
KR20010033520A (ko) 2001-04-25
CN1163477C (zh) 2004-08-25
EP1042279A1 (de) 2000-10-11
AU1771999A (en) 1999-07-19
ATE289991T1 (de) 2005-03-15
JP4555469B2 (ja) 2010-09-29
WO1999033789A1 (en) 1999-07-08
NO20003273L (no) 2000-06-22
SK9372000A3 (en) 2002-03-05

Similar Documents

Publication Publication Date Title
IL136584A0 (en) SUBSTITUTED β- ALANINES
CA2303848A1 (en) Substituted anilides
HUP0204496A2 (en) Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same
TR200102959T2 (tr) İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
ATE206611T1 (de) Verwendung von mangiferin oder seinen derivaten zur kosmetischen anwendung
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
HU9603185D0 (en) New azolidinediones as antihyperglycemic agents
HUP0001192A2 (hu) Topiramát és származékainak alkalmazása elhízás kezelésére használható gyógyszerkészítmények előállítására
GB9408185D0 (en) New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DE69225244D1 (de) Inhibitoren von testosteron-5-alpha reductase.
JO2321B1 (en) 4-phenyl-pyridine derivatives
CO4820432A1 (es) Composiciones farmaceuticas para el tratamiento de rinitis que comprenden acido 2-(4-(difenilmetil)-1-piperacinil)-ace- tico o amida derivada y un compuesto seleccionado de pseudoe fedrina,fenilpropanolamina y fenilefrina
NO944892D0 (no) N-substituerte 3-azabicyklo (3.2.0) hepatanderivater som neuroleptika osv.
EP0638564A4 (de) Benzothiazolsulfonamid-derivate, verfahren zu deren herstellung und anwendungen.
ES8107213A1 (es) Procedimiento de preparacion de nuevos derivados n-sustitui-dos de tetrahidropiridinil-indol
ZA9429B (en) Pyrrolidine derivatives their preparation and medicaments containing them
HU9500175D0 (en) Pharmacologically active alpha-[tertiary-aminomethyl]-benzenemethanol derivatives
ATE245986T1 (de) Verwendung von 8-nitro-2,3,4,5-tetrahydro-1h-3- benzazepinen zur herstellung von pharmazeutischen zusammenstellungen zur behandlung von schlafstörungen
AU2621995A (en) Indole derivatives as prodrugs of 5-ht1-like receptor agonists
TR200402493T4 (tr) Yeni 2,3-benzodiazepin türevleri ve aktif bileşen olarak bunları içeren farmasötik bileşimler.
AU561092B2 (en) N-(2,6 disubstituted aromatic)-n:-pyridinyl ureas
BR9507668A (pt) Intermédio para preparar um composto farmaceuticamente atívo

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees